UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

              Current Report Pursuant to Section 13 or 15(d) of the
                        Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): September 29, 2005

                         Calypte Biomedical Corporation
               (Exact name of Company as specified in its charter)

<TABLE>
<S>                            <C>                                 <C>
Delaware                       000-20985                           06-1226727
(State or Other Jurisdiction)  (Commission File Number)  (I.R.S. Employer Identification)
of Incorporation)
</TABLE>

             5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
              (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282

                                       N/A

          (Former name or former address, if changed since last report)

|_|   Written  communication  pursuant to Rule 425 under the  Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 40.13e-4(c))

<PAGE>

Item 5.02   Departure  of  Directors  or  Principal  Officers;  Election  of
            Directors; Appointment of Principal Officers.

(b) On September 29, 2005, J. Richard  George,  Ph.D.  resigned as President and
Chief   Executive   officer  of  Calypte   Biomedical   Corporation,   effective
immediately.

         On October 3, 2005,  Richard D. Brounstein  ceased to hold the position
of Chief Financial  Officer of Calypte  Biomedical  Corporation.  Mr. Brounstein
will continue as the Company's Executive Vice President.

         On  October  3,  2005,   Richard  R.  Van  Maanen   resigned   as  Vice
President-Operations  and International Business Development,  effective October
7, 2005.

(c) On October 5, 2005, the Company's board of directors appointed its Chairman,
Roger I. Gale, as interim Chief Executive Officer,  effective  immediately.  Mr.
Gale was appointed to the Company's  Board of Directors and elected  Chairman in
November 2004.  Mr. Gale has served since October 2001 as Executive  Chairman of
the  Board  of  Directors  of  Wavecrest  Group  Enterprises  Limited,  a United
Kingdom-based communications service provider. He is also a founder and director
of Starnorth Limited, a communications and media consultancy. From 1999 to 2001,
he was Chairman and co-founder of End2End Wireless Limited, a UK wireless access
services  provider.  He has  previously  held  senior  positions  with the Asian
Development Bank (ADB, Manila) and the International  Finance Corporation (IFC),
the private sector arm of the World Bank in  Washington,  D.C. Mr. Gale has also
lectured in economics at the University of New England  (Australia)  and Lincoln
College  (New  Zealand).  He  serves  as a  Director  and a member  of the Audit
Committee  of Mechel  Steel  Group,  (NYSE:  MTL).  Mr.  Gale  holds a Master of
Economics  degree from the  University of New England,  Australia,  and a Higher
National   Diploma   from   the   Royal   Agricultural   College,   Cirencester,
Gloucestershire,  England.  Mr. Gale is one of two  Directors  appointed  to the
Company's  Board  pursuant to an August 2003  agreement  between the Company and
Marr  Technologies  BV  ("Marr").   Marr  is  currently  the  Company's  largest
stockholder,  holding  approximately  27% of the  Company's  outstanding  common
stock.

         Effective October 3, 2005, the Company has promoted Theodore R. Gwin to
the position of Chief  Financial  Officer  (principal  financial and  accounting
officer),  replacing Richard D. Brounstein. Mr. Gwin has served as the Company's
Controller  since April 2005.  Prior to joining the  Company,  from January 2001
through April 2005, Mr. Gwin had worked as an independent financial and business
consultant to companies in various industries,  including biotechnology,  in the
Portland,  Oregon area. From April 1998 through  December 2000, Mr. Gwin was the
Controller  and  Principal  Accounting  Officer  at OraSure  Technologies,  Inc.
(Nasdaq: OSUR), formerly Epitope, Inc.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1   Press release dated October 6, 2005.

<PAGE>

                                   SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  Lake Oswego, Oregon
       October 6, 2005

                         Calypte Biomedical Corporation

                                            By: /s/  Richard D. Brounstein
                                                --------------------------------
                                                     Richard D. Brounstein
                                                     Executive Vice President
{"company-data": {"conformed-name": "CALYPTE BIOMEDICAL CORP", "cik": "0000899426", "assigned-sic": "3826", "irs-number": "061226727", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32280", "film-number": "051126216"}, "business-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588", "phone": "9257307200"}, "mail-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

              Current Report Pursuant to Section 13 or 15(d) of the
                        Securities Exchange Act of 1934

      Date of Report (Date of earliest event reported): September 29, 2005

                         Calypte Biomedical Corporation
               (Exact name of Company as specified in its charter)
Delaware                       000-20985                           06-1226727
(State or Other Jurisdiction)  (Commission File Number)  (I.R.S. Employer Identification)
of Incorporation)
5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
              (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282

                                       N/A

          (Former name or former address, if changed since last report)

|_|   Written  communication  pursuant to Rule 425 under the  Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 40.13e-4(c))
Item 5.02   Departure  of  Directors  or  Principal  Officers;  Election  of
            Directors; Appointment of Principal Officers.

(b) On September 29, 2005, J. Richard  George,  Ph.D.  resigned as President and
Chief   Executive   officer  of  Calypte   Biomedical   Corporation,   effective
immediately.

         On October 3, 2005,  Richard D. Brounstein  ceased to hold the position
of Chief Financial  Officer of Calypte  Biomedical  Corporation.  Mr. Brounstein
will continue as the Company's Executive Vice President.

         On  October  3,  2005,   Richard  R.  Van  Maanen   resigned   as  Vice
President-Operations  and International Business Development,  effective October
7, 2005.

(c) On October 5, 2005, the Company's board of directors appointed its Chairman,
Roger I. Gale, as interim Chief Executive Officer,  effective  immediately.  Mr.
Gale was appointed to the Company's  Board of Directors and elected  Chairman in
November 2004.  Mr. Gale has served since October 2001 as Executive  Chairman of
the  Board  of  Directors  of  Wavecrest  Group  Enterprises  Limited,  a United
Kingdom-based communications service provider. He is also a founder and director
of Starnorth Limited, a communications and media consultancy. From 1999 to 2001,
he was Chairman and co-founder of End2End Wireless Limited, a UK wireless access
services  provider.  He has  previously  held  senior  positions  with the Asian
Development Bank (ADB, Manila) and the International  Finance Corporation (IFC),
the private sector arm of the World Bank in  Washington,  D.C. Mr. Gale has also
lectured in economics at the University of New England  (Australia)  and Lincoln
College  (New  Zealand).  He  serves  as a  Director  and a member  of the Audit
Committee  of Mechel  Steel  Group,  (NYSE:  MTL).  Mr.  Gale  holds a Master of
Economics  degree from the  University of New England,  Australia,  and a Higher
National   Diploma   from   the   Royal   Agricultural   College,   Cirencester,
Gloucestershire,  England.  Mr. Gale is one of two  Directors  appointed  to the
Company's  Board  pursuant to an August 2003  agreement  between the Company and
Marr  Technologies  BV  ("Marr").   Marr  is  currently  the  Company's  largest
stockholder,  holding  approximately  27% of the  Company's  outstanding  common
stock.

         Effective October 3, 2005, the Company has promoted Theodore R. Gwin to
the position of Chief  Financial  Officer  (principal  financial and  accounting
officer),  replacing Richard D. Brounstein. Mr. Gwin has served as the Company's
Controller  since April 2005.  Prior to joining the  Company,  from January 2001
through April 2005, Mr. Gwin had worked as an independent financial and business
consultant to companies in various industries,  including biotechnology,  in the
Portland,  Oregon area. From April 1998 through  December 2000, Mr. Gwin was the
Controller  and  Principal  Accounting  Officer  at OraSure  Technologies,  Inc.
(Nasdaq: OSUR), formerly Epitope, Inc.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1   Press release dated October 6, 2005.
SIGNATURES

Pursuant  to the  requirement  of the  Securities  Exchange  Act  of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  Lake Oswego, Oregon
       October 6, 2005

                         Calypte Biomedical Corporation

                                            By: /s/  Richard D. Brounstein
                                                --------------------------------
                                                     Richard D. Brounstein
                                                     Executive Vice President